Windtree reports positive Phase 2b study on heart failure therapy
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...
Simple congenital heart diseases tied to higher epilepsy risk
Among simple congenital heart diseases (CHD), patent foramen ovale (PFO) is associated with a significantly higher risk for ...
Science Daily21h
Born to heal: Why babies recover, but adults scar, after heart damage
Newborns with heart complications can rely on their newly developed immune systems to regenerate cardiac tissues, but adults aren't so lucky. After a heart attack, most adults struggle to regenerate ...
Mechanical heart valve replacements have better long-term survival, study finds
Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to ...
Business Wire22h
Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial
Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) ...